tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Geoff Meacham, 221 are a BUY (61.9%), 107 are a HOLD (29.97%), 29 are a SELL (8.12%).
Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 65.46% that have a potential upside of 35.16% achieved within 240 days.
Geoff Meacham’s has documented 733 price targets and ratings displayed on 56 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on AMGN, Amgen at 22-Jul-2025.
Analyst best performing recommendations are on LYEL (LYELL IMMUNOPHARMA).
The best stock recommendation documented was for LYEL (LYELL IMMUNOPHARMA) at 10/30/2024. The price target of $1 was fulfilled within 2 days with a profit of $0.14 (16.28%) receiving and performance score of 81.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
4 years 3 months 1 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 3 months 3 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 3 months 11 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 6 months 2 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 6 months 30 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Geoff Meacham is most bullish on?
Which stock is Geoff Meacham is most reserved on?
What Year was the first public recommendation made by Geoff Meacham?
